CFDA officially joined the interim stage management committee of the international drug regulatory agency Alliance

Source: CFDA 2015-6-25 The alliance is a new international cooperation mechanism positioned at the level of heads of drug regulatory agencies in various countries The purpose is to strengthen strategic planning, innovate regulatory means, improve the management efficiency of international cooperation, effectively use resources, promote drug regulatory cooperation, and promote the convergence of regulatory mechanisms for the entire life cycle of drugs on the basis of making full use of and guiding existing international cooperation actions And provide capacity-building support for national drug regulatory agencies At present, there are 13 national and regional drug regulatory agencies including China, Canada, Ireland, the United States, Brazil, the European Union, Italy, the Netherlands, Singapore, Japan, Australia, South Africa and the United Kingdom Officially joining the interim stage management committee of the international drug regulatory agency alliance will help the general administration learn from the successful experience of international drug regulation, understand and master the international prevailing rules and standards, improve the international level of drug regulation, and promote the overall improvement of the level of drug regulation in China At the same time, it will also help the general administration to further play an active role in the multilateral diplomatic platform, strive to use many side resources, and carry out regulatory cooperation in the strategic priority areas of concern, so as to strive for more benefits for China.